Literature DB >> 23942203

Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.

Julien Tarabeux1, Bruno Zeitouni2, Virginie Moncoutier3, Henrique Tenreiro3, Khadija Abidallah3, Séverine Lair2, Patricia Legoix-Né4, Quentin Leroy4, Etienne Rouleau3, Lisa Golmard1, Emmanuel Barillot2, Marc-Henri Stern1, Thomas Rio-Frio4, Dominique Stoppa-Lyonnet5, Claude Houdayer5.   

Abstract

To meet challenges in terms of throughput and turnaround time, many diagnostic laboratories are shifting from Sanger sequencing to higher throughput next-generation sequencing (NGS) platforms. Bearing in mind that the performance and quality criteria expected from NGS in diagnostic or research settings are strikingly different, we have developed an Ion Torrent's PGM-based routine diagnostic procedure for BRCA1/2 sequencing. The procedure was first tested on a training set of 62 control samples, and then blindly validated on 77 samples in parallel with our routine technique. The training set was composed of difficult cases, for example, insertions and/or deletions of various sizes, large-scale rearrangements and, obviously, mutations occurring in homopolymer regions. We also compared two bioinformatic solutions in this diagnostic context, an in-house academic pipeline and the commercially available NextGene software (Softgenetics). NextGene analysis provided higher sensitivity, as four previously undetected single-nucleotide variations were found. Regarding specificity, an average of 1.5 confirmatory Sanger sequencings per patient was needed for complete BRCA1/2 screening. Large-scale rearrangements were identified by two distinct analyses, that is, bioinformatics and fragment analysis with electrophoresis profile comparison. Turnaround time was enhanced, as a series of 30 patients were sequenced by one technician, making the results available for the clinician in 10 working days following blood sampling. BRCA1/2 genes are a good model, representative of the difficulties commonly encountered in diagnostic settings, which is why we believe our findings are of interest for the whole community, and the pipeline described can be adapted by any user of PGM for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942203      PMCID: PMC3953907          DOI: 10.1038/ejhg.2013.181

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  20 in total

1.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.

Authors:  Jan P Schouten; Cathal J McElgunn; Raymond Waaijer; Danny Zwijnenburg; Filip Diepvens; Gerard Pals
Journal:  Nucleic Acids Res       Date:  2002-06-15       Impact factor: 16.971

2.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.

Authors:  Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo
Journal:  Genome Res       Date:  2010-07-19       Impact factor: 9.043

3.  An integrated semiconductor device enabling non-optical genome sequencing.

Authors:  Jonathan M Rothberg; Wolfgang Hinz; Todd M Rearick; Jonathan Schultz; William Mileski; Mel Davey; John H Leamon; Kim Johnson; Mark J Milgrew; Matthew Edwards; Jeremy Hoon; Jan F Simons; David Marran; Jason W Myers; John F Davidson; Annika Branting; John R Nobile; Bernard P Puc; David Light; Travis A Clark; Martin Huber; Jeffrey T Branciforte; Isaac B Stoner; Simon E Cawley; Michael Lyons; Yutao Fu; Nils Homer; Marina Sedova; Xin Miao; Brian Reed; Jeffrey Sabina; Erika Feierstein; Michelle Schorn; Mohammad Alanjary; Eileen Dimalanta; Devin Dressman; Rachel Kasinskas; Tanya Sokolsky; Jacqueline A Fidanza; Eugeni Namsaraev; Kevin J McKernan; Alan Williams; G Thomas Roth; James Bustillo
Journal:  Nature       Date:  2011-07-20       Impact factor: 49.962

4.  Next-generation sequencing meets genetic diagnostics: development of a comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.

Authors:  Lídia Feliubadaló; Adriana Lopez-Doriga; Ester Castellsagué; Jesús del Valle; Mireia Menéndez; Eva Tornero; Eva Montes; Raquel Cuesta; Carolina Gómez; Olga Campos; Marta Pineda; Sara González; Victor Moreno; Joan Brunet; Ignacio Blanco; Eduard Serra; Gabriel Capellá; Conxi Lázaro
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

5.  Carrier testing for severe childhood recessive diseases by next-generation sequencing.

Authors:  Callum J Bell; Darrell L Dinwiddie; Neil A Miller; Shannon L Hateley; Elena E Ganusova; Joann Mudge; Ray J Langley; Lu Zhang; Clarence C Lee; Faye D Schilkey; Vrunda Sheth; Jimmy E Woodward; Heather E Peckham; Gary P Schroth; Ryan W Kim; Stephen F Kingsmore
Journal:  Sci Transl Med       Date:  2011-01-12       Impact factor: 17.956

6.  BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group.

Authors:  D Stoppa-Lyonnet; P Laurent-Puig; L Essioux; S Pagès; G Ithier; L Ligot; A Fourquet; R J Salmon; K B Clough; P Pouillart; C Bonaïti-Pellié; G Thomas
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

7.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data.

Authors:  Kai Wang; Mingyao Li; Hakon Hakonarson
Journal:  Nucleic Acids Res       Date:  2010-07-03       Impact factor: 16.971

8.  Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.

Authors:  Patrícia M Machado; Rita D Brandão; Branca M Cavaco; Joana Eugénio; Sandra Bento; Mónica Nave; Paula Rodrigues; Aires Fernandes; Fátima Vaz
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

9.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences.

Authors:  Jeremy Goecks; Anton Nekrutenko; James Taylor
Journal:  Genome Biol       Date:  2010-08-25       Impact factor: 13.583

10.  Differential expression analysis for sequence count data.

Authors:  Simon Anders; Wolfgang Huber
Journal:  Genome Biol       Date:  2010-10-27       Impact factor: 13.583

View more
  29 in total

1.  Evaluation of a new high-throughput next-generation sequencing method based on a custom AmpliSeq™ library and ion torrent PGM™ sequencing for the rapid detection of genetic variations in long QT syndrome.

Authors:  Gilles Millat; Valérie Chanavat; Robert Rousson
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

2.  Validation of an NGS Approach for Diagnostic BRCA1/BRCA2 Mutation Testing.

Authors:  Daniela Dacheva; Rumyana Dodova; Ivan Popov; Teodora Goranova; Atanaska Mitkova; Vanio Mitev; Radka Kaneva
Journal:  Mol Diagn Ther       Date:  2015-04       Impact factor: 4.074

3.  Mosaicism and prenatal diagnosis options: insights from retinoblastoma.

Authors:  Catherine Dehainault; Lisa Golmard; Gaël A Millot; Agathe Charpin; Anthony Laugé; Julien Tarabeux; Isabelle Aerts; Nathalie Cassoux; Dominique Stoppa-Lyonnet; Marion Gauthier-Villars; Claude Houdayer
Journal:  Eur J Hum Genet       Date:  2016-12-21       Impact factor: 4.246

4.  Diagnostic Screening Workflow for Mutations in the BRCA1 and BRCA2 Genes.

Authors:  Stella Lai; Clare Brookes; Debra O Prosser; Chuan-Ching Lan; Elaine Doherty; Donald R Love
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

5.  Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations.

Authors:  L Golmard; C Delnatte; A Laugé; V Moncoutier; C Lefol; K Abidallah; H Tenreiro; F Copigny; M Giraudeau; C Guy; C Barbaroux; G Amorim; A Briaux; V Guibert; J Tarabeux; S Caputo; A Collet; P Gesta; O Ingster; M-H Stern; E Rouleau; A de Pauw; M Gauthier-Villars; B Buecher; S Bézieau; D Stoppa-Lyonnet; C Houdayer
Journal:  Oncogene       Date:  2015-06-01       Impact factor: 9.867

6.  Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.

Authors:  Ronald Lebofsky; Charles Decraene; Virginie Bernard; Maud Kamal; Anthony Blin; Quentin Leroy; Thomas Rio Frio; Gaëlle Pierron; Céline Callens; Ivan Bieche; Adrien Saliou; Jordan Madic; Etienne Rouleau; François-Clément Bidard; Olivier Lantz; Marc-Henri Stern; Christophe Le Tourneau; Jean-Yves Pierga
Journal:  Mol Oncol       Date:  2014-12-26       Impact factor: 6.603

7.  Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.

Authors:  Laurent Castéra; Sophie Krieger; Antoine Rousselin; Angélina Legros; Jean-Jacques Baumann; Olivia Bruet; Baptiste Brault; Robin Fouillet; Nicolas Goardon; Olivier Letac; Stéphanie Baert-Desurmont; Julie Tinat; Odile Bera; Catherine Dugast; Pascaline Berthet; Florence Polycarpe; Valérie Layet; Agnes Hardouin; Thierry Frébourg; Dominique Vaur
Journal:  Eur J Hum Genet       Date:  2014-02-19       Impact factor: 4.246

8.  New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing.

Authors:  Anna Kluska; Aneta Balabas; Agnieszka Paziewska; Maria Kulecka; Dorota Nowakowska; Michal Mikula; Jerzy Ostrowski
Journal:  BMC Med Genomics       Date:  2015-05-07       Impact factor: 3.063

Review 9.  Next-generation sequencing in clinical oncology: next steps towards clinical validation.

Authors:  Nigel C Bennett; Camile S Farah
Journal:  Cancers (Basel)       Date:  2014-11-18       Impact factor: 6.639

10.  Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2.

Authors:  Michael Dean; Joseph Boland; Meredith Yeager; Kate M Im; Lisa Garland; Maria Rodriguez-Herrera; Mylen Perez; Jason Mitchell; David Roberson; Kristine Jones; Hyo Jung Lee; Rebecca Eggebeen; Julie Sawitzke; Sara Bass; Xijun Zhang; Vivian Robles; Celia Hollis; Claudia Barajas; Edna Rath; Candy Arentz; Jose A Figueroa; Diane D Nguyen; Zeina Nahleh
Journal:  Gigascience       Date:  2015-11-04       Impact factor: 6.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.